Bimekizumab, a bispecific mAb inhibits IL-7F & IL-17A, was testedin PhIII trial in Active psoriasis and show to be more effective than ustekinumab and placebo. 567 PSO pts - at wk 16, PASI90 was BMKZ 85% vs Ustekinumab 50%, vs 5% in placeob (p<0·0001) https://t.co/Z4ZQEHO4rX